peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Our leadership

Executive Commitee

Søren Tulstrup
President and Chief Executive Officer

Søren Tulstrup has served as President and Chief Executive Officer since March 2018. He has extensive experience as a senior executive in the global biopharma industry. Prior to joining Hansa, Søren served as Chief Executive Officer of Vifor Pharma AG (SIX: VIFN), (now part of CSL Behring), and he has also served as President & Chief Executive Officer of Santaris Pharma A/S (now part of F. Hoffmann-La Roche AG (SIX: ROG)). Furthermore, Søren has served in several senior general management and commercial roles within Shire Pharmaceuticals (now The Takeda Pharmaceutical Company Limited (TSE: 4502)), Merck & Co., Inc. (NYSE: MRK) and Sandoz Pharma AG (now Novartis AG, or Novartis (NYSE: NVS)) in both Europe and the United States. He holds a Master of Science, Economics and Business Administration from Copenhagen Business School.

Shareholding: 50,347
Share rights: 260,000
ESOP's: 575,107

Anne Säfström Lanner
Senior Vice President, Chief Human Resources Officer

Anne Säfström Lanner has served as Chief Human Resources Officer since June 2020, and served as Vice President Global Human Resources from 2019 to June 2020. Prior to joining Hansa, she served in various senior roles at the European Spallation Source, a European multi-disciplinary research facility, including Head of Resourcing. Prior to that, Head of Human Resources at Cellavision AB (STO:CEVI). Anne has held positions as Head of HR, Head of Resourcing, HR Manager & Deputy Head of HR and has extensive experience from fast growing start-up international companies. Holds a Bachelor of Social Science in Human Resource Management, focusing on strategic organizational development & leadership, from Lund University.

Shareholding: 7 273
Share rights: 125 000
ESOP's: 160 000

Matthew Shaulis
Chief Commercial Officer and US President

Matthew Shaulis has served as Chief Commercial Officer and President of the U.S. affiliate, Hansa Biopharma Inc since March 2023. Prior to his role at Hansa Biopharma, Matthew gained over 20 years of US and international experience in the pharmaceutical industry in general management, global strategic and in-line marketing, sales management, business development, and product and indication launches. He held several senior executive roles at Pfizer Inc. (NYSE: PFE), including President of Inflammation & Immunology for International markets in Europe and Asia, President of Oncology for North America, and more recently as the Senior Vice President responsible for leading the company’s global commercial and medical go-to-market model transformation. Prior to that, Matthew served in various leadership roles at Teva Pharmaceutical Industries (NYSE: TEVA), Cephalon, Johnson & Johnson (LSE: JNJ), and Schering-Plough (now part of Merck & Co., Inc. (NYSE: MRK)). He holds a B.S. in Accounting from Pennsylvania State University and an M.B.A. from The Fuqua School of Business, Duke University, North Carolina.

Shareholding: –
Share rights: 105 000
ESOs: 128 300

Hitto Kaufmann
Chief R&D Officer

Hitto Kaufmann has served as Chief Scientific Officer and then Chief R&D Officer since December 2023. Hitto has over 20 years’ experience as biopharma leader in the development of innovative medicines, advancement of strategic R&D partnerships, and building of next generation therapeutic platforms. His track record includes the development of approximately 100 biological therapeutic entities, many of them advanced by him actively steering strategic partnerships. Prior to joining Hansa, Hitto served as Chief Scientific Officer at Pieris Pharmaceuticals, directing discovery, technical development, CMC, data sciences, project management and alliance management departments. He furthermore was appointed site head of the R&D site of Pieris in Munich.
Before his tenure at Pieris he spent 5 years at Sanofi where he held several executive positions in Industrial Affair and Sanofi R&D. He led efforts to build a strong cross-divisional end-to-end technology platform for biologics including several strategic deals before becoming the Global Head of Biopharmaceutics Development. During more than a decade at Boehringer Ingelheim he held several leadership positions including Vice President, Process Sciences. He began his career as a Research Scientist at the Walter and Eliza Hall Institute in Melbourne. Hitto currently serves as a member of the Scientific Advisory Board of Instituto de Biologia Experimental e Tecnologica (iBET). He holds a Ph.D. in Natural Science, from the Swiss Federal Institute of Technology in Zurich.

Share rights: 60 000
ESOP's: 70 000

Evan Ballantyne
Chief Financial Officer

Evan Ballantyne has served as Chief Financial Officer, Hansa Biopharma since March 2024.He has over 30 years of international financial and operational experience as a senior financial executive in both public and private life science companies. Prior to Hansa, Evan served as CFO at Gain Therapeutics, Inc. (NASDAQ: GANX). Evan also worked at OnXerna Therapeutics, Inc., Agenus (NASDAQ: AGEN) and Clinical Data (NASDAQ: CLDA) where he helped lead the sale of the company to Forrest Labs (now Allergan) for $1.2 billion. During his career, Evan has held roles of increasing responsibility at biotech, medical technology and information services companies throughout Europe and the US, helping these companies navigate complex financial markets and secure funding and capital to support their growth. Evan has a degree in Honors Business Administration from the University of Windsor, Ontario Canada as well as a BA in American History & Political Science from the University of Western Ontario, Canada. He is an independent board member of Preveceutical Medical, Inc in Vancouver, British Columbia, Canada.

Shareholding: -
Share rights:

Board of Directors

Peter Nicklin
Member and Chair of the Board since 2022

Peter Nicklin has more than 30 years of extensive experience and background in the pharmaceutical and healthcare sector in both developed, as well as emerging markets and significant experience in leading global teams. Chair of the Board at Tunstall Healthcare and Sciensus. Previously, CEO and member of the Board of Amann Girrbach AG, Corporate Vice President and EMEA President of Baxter International (NYSE: BAX), as well as senior executive roles at Bayer Healthcare (XETRA: BAYN), Novartis (SWX: NOVN) and Bristol-Myers Squibb (NYSE:BMY). Peter holds a Bachelor of Arts with Honours in Finance from Lancaster University. He is also a Chartered Accountant having qualified at PriceWaterhouseCoopers in London.

Member and chair of the Board since 2022, member of the Remuneration Committee, the Scientific Committee and the US Committee. Independent of Hansa Biopharma and its executive management. Independent of major shareholders of Hansa Biopharma.
Shareholding: 15,500

Eva Nilsagård
Member of the board since 2019

Eva Nilsagård is the founder and Chief Executive Officer of Nilsagård Consulting AB. Previous interim Chief Financial Officer of various companies, including OptiGroup AB, Plastal, and Vitrolife AB. She has also served in various senior positions at the Volvo Group, or Volvo, including Senior Vice President Strategy & Business Development. Earlier in her career, Eva also held senior positions in finance and business development at AstraZeneca plc and AB SKF. Board member and chair of the audit committee of SEK (Swedish Export Credit Company), AddLife, Bufab Group, Irras AB, Nimbus Group AB, Nanexa, Ernströmgruppen and Xbrane Biopharma, the chair of Spermosens AB, and board member of eEducation Albert AB. Eva has more than ten years of
experience as a mentor for young female managers with high potential. She holds an Executive M.B.A. in Economics and a B.Sc. in accounting and finance from School of Business, Economics and Law in Gothenburg.

Member of the Board since 2019 and chair of the Audit Committee.
Independent of Hansa Biopharma and its executive management. Independent of major shareholders of Hansa Biopharma.

Shareholding: 3,000

Mats Blom
Member of the board since 2019

Mats Blom serves as Chief Financial Officer of NorthSea Therapeutics B.V. Previous Chief Financial Officer of Modus Therapeutics AB, Zealand Pharma A/S, Swedish Orphan International AB (acquired by BioVitrum, now Swedish Orphan Biovitrum AB), Active Biotech AB, and Anoto Group AB. Previously also management consultant at Gemini Consulting and Ernst & Young. Chairman of The Board of Egetis Therapeutics AB. Board member of Altamira Therapeutics Ltd., and Pephexia Therapeutics ApS. Mats holds a B.A. in Business Administration and Economics from
Lund University and an M.B.A. from the IESE University of Navarra, Barcelona

Member of the Board since 2019 and member of the Audit Committee.
Independent of Hansa Biopharma and its executive management. Independent of major shareholders of Hansa Biopharma.

Shareholding: 1,000

Hilary M. Malone
Member of the board since 2021

Hilary Malone has over 25 years of experience in global drug development, regulatory and government affairs, manufacturing and commercialization within the pharmaceutical industry. She has served as Chief Executive Officer of a private life sciences company in start-up phase since November 2021. She previously served as Chief Operating Officer and Executive Vice President at Valo Health Inc., and as the Chief Regulatory Officer and Senior Vice President & Head of Global Regulatory Affairs at Sanofi Inc. (subsidiary of Sanofi SA). Previous experience also includes senior regulatory and drug development roles at Reata Pharmaceuticals, Inc., Pfizer Inc., Wyeth, LLC (acquired by Pfizer Inc.), AstraZeneca plc and GlaxoSmithKline plc. Hilary has also served on the board of Inhibikase Therapeutics. She holds a Ph.D. in Molecular Neuropharmacology and a B.Sc. in Physiology from the University of Dundee, Scotland. She is a U.S., U.K., and Irish citizen.

Member of the Board since 2021, chair of the US Committee, and member of the
Scientific Committee.
Independent of Hansa Biopharma and its executive management. Independent of major shareholders of Hansa Biopharma.

Shareholding: -

Andreas Eggert
Member of the Board since 2018

Andreas Eggert has over 25 years of cross-functional leadership experience including commercial operations, launch and portfolio management, brand strategy, market access, and strategic consulting. Chief Operating Officer at X-Vax Technology Inc. in the U.S. Previously, served as Senior Group Vice President, Global Product Strategy & Portfolio Development, and member of the Corporate Management Committee at H. Lundbeck A/S in Denmark. Previously, also served in various senior commercial roles at Wyeth, LLC (acquired by Pfizer Inc.) in the U.S., Japan and in Germany, including as Vice President & Global Business Manager. Earlier in his career, Andreas also was a Management Consultant at A.T. Kearney. He holds an M.B.A. from Azusa Pacific University.

Member of the Board since 2018, chair of the Remuneration Committee, and member of the Audit Committee and the Scientific Committee.
Independent of Hansa Biopharma and its executive management. Independent of major shareholders of Hansa Biopharma.

Shareholding: 5,500

Anders Gersel Pedersen
Member of the Board since 2018

Anders Gersel Pedersen has over 33 years of experience in the international pharmaceutical industry. Served in various roles at H. Lundbeck A/S in Denmark (CSE: LUN), including most recently as Executive Vice President of Research & Development, as responsible for the discovery and development of the product pipeline from preclinical activities to post-launch marketing studies. Prior to that, served in various roles at Eli Lilly and Company, including most recently as a director overseeing worldwide clinical research in oncology. Anders is Chairman at Aelis and Deputy Chair at Bavarian. Serves on the supervisory boards of Avillion LLP, Bavarian Nordic A/S, AELIS Farma SA, and Genmab A/S. He received his medical degree and a doctoral degree in neuro-oncology from the University of Copenhagen and a B.Sc. in Business Administration from Copenhagen Business School.

Member of the Board since 2018, chair of the Scientific Committee, and member of the Remuneration Committee.
Independent of Hansa Biopharma and its executive management. Independent of major shareholders of Hansa

Shareholding: 2,500